Top ▲

Plasmodium vivax

Species ID:104
Name:Plasmodium vivax
Associated with:2 targets
4 ligands
P. vivax (Pv) is one of five protozoan parasite species of the genus Plasmodium that cause malaria in humans. Pv is the second most common cause of malaria in humans, after P. falciparum, and is prevalent in Southeast Asia and Latin America. Pv has a dormant liver stage that can reactivate and lead to clinical symptoms.


Key to terms and symbols Click column headers to sort
Target Ligand Sp. Action Value Parameter Reference
Plasmodium falciparum dihydroorotate dehydrogenase DSM265 Pv Inhibition 7.1 pIC50 2
pIC50 7.1 (IC50 7.2x10-8 M) [2]
Description: Steady-state kinetic analysis.
Plasmodium falciparum dihydroorotate dehydrogenase DSM421 Pv - 6.7 pEC50 3
pEC50 6.7 (EC50 1.8x10-7 M) [3]
Lifecycle stages: Plasmodium asexual blood stage (erythrocytic merozoite, trophozoite, erythrocytic schizont)
Description: Blood-stage: schizont maturation assay using P. vivax field isolates.
Plasmodium falciparum dihydroorotate dehydrogenase DSM421 Pv Inhibition 7.0 pIC50 3
pIC50 7.0 (IC50 9.4x10-8 M) [3]
Description: Steady-state kinetic analysis of recombinant enzyme inhibition.
Plasmodium falciparum dihydroorotate dehydrogenase DSM502 Pv Inhibition 7.8 pIC50 2
pIC50 7.8 (IC50 1.4x10-8 M) [2]
Description: Steady-state kinetic analysis.
Plasmodium falciparum lysine--tRNA ligase compound 5 [PMID: 30894487] Pv - 6.0 pEC50 1
pEC50 6.0 (EC50 9.5x10-7 M) [1]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay


Show »

1. Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C et al.. (2019) Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc Natl Acad Sci USA, 116 (14): 7015-7020. [PMID:30894487]

2. Kokkonda S, Deng X, White KL, El Mazouni F, White J, Shackleford DM, Katneni K, Chiu FCK, Barker H, McLaren J et al.. (2020) Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria. J Med Chem, 63 (9): 4929-4956. [PMID:32248693]

3. Phillips MA, White KL, Kokkonda S, Deng X, White J, El Mazouni F, Marsh K, Tomchick DR, Manjalanagara K, Rudra KR et al.. (2016) A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infect Dis, 2 (12): 945-957. [PMID:27641613]